Singular Genomics Systems Inc   (OMIC)
Other Ticker:  
Price: $0.4010 $-0.02 -5.358%
Day's High: $0.4247 Week Perf: -17.3 %
Day's Low: $ 0.36 30 Day Perf: -29.49 %
Volume (M): 283 52 Wk High: $ 1.21
Volume (M$): $ 114 52 Wk Avg: $0.60
Open: $0.42 52 Wk Low: $0.31

 Market Capitalization (Millions $) 29
 Shares Outstanding (Millions) 73
 Employees -
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) 89
 Cash Flow (TTM) (Millions $) -60
 Capital Exp. (TTM) (Millions $) 2

Singular Genomics Systems Inc
Singular Genomics Systems Inc. is a biotechnology company that specializes in single-cell genomics technology. The company develops and commercializes innovative solutions for the analysis of individual cells with the goal of understanding the genetic makeup and functionality of diverse cell populations. Their technology allows researchers and scientists to study and analyze genetic information at the single-cell level, providing valuable insights into complex biological systems and diseases. Singular Genomics Systems Inc. aims to contribute to advancements in precision medicine, drug discovery, and various areas of life science research.

   Company Address: 3010 Science Park Road San Diego 92121 CA
   Company Phone Number: 333-7830   Stock Exchange / Ticker: NASDAQ OMIC


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Product Service News

Unlocking the Genomics Universe: Singular Genomics Unveils the Futuristic G4X Spatial Sequencer at AGBT Conference

Published Mon, Feb 5 2024 3:55 PM UTC

Singular Genomics Unveils Game-Changing G4X Spatial Sequencer at AGBT ConferenceSingular Genomics Systems, a leading provider of next-generation sequencing (NGS) technologies, made waves at the Advances of Genome Biology and Technology (AGBT) conference in Orlando, Florida, with the launch of its highly anticipated G4X Spatial Sequencer. With this groundbreaking new product,...

Singular Genomics Systems Inc

Singular Genomics Systems Inc Struggles with Dismal Revenue and Inventory Decline in Q3 2023

The Laboratory Analytical Instruments company, Singular Genomics Systems Inc, reported limited revenue of only $0.462 million in the third quarter of 2023. Moreover, the company experienced a net loss of an alarming $-22.360 million in the same quarter, a significant deterioration compared to the previous year's deficit of $-23.790 million. Furthermore, inventories have declined to $13.4 million, indicating potential weakening future demand. These factors, coupled with other concerning indicators, suggest a bearish outlook for Singular Genomics Systems Inc.
Declining Inventories Reflect Lower Demand:
A critical aspect to assess a company's growth prospects lies in its inventory levels, which provide insight into future demand. Singular Genomics Systems Inc witnessed a decline in inventories to $13.4 million in the third quarter, compared to the previous quarter as well as the same period a year before. This reduction raises concerns about weakening demand and potential challenges the company may face in generating future revenue.

Singular Genomics Systems Inc

Singular Genomics Systems Inc Faces Financial Crisis with Only $0.505 Million in Revenue and Growing Net Loss in Q2 2023

In the latest fiscal time-frame ending June 30th, 2023, Singular Genomics Systems Inc, a prominent player in the industry, has reported disappointing financial results. With only $0.505 million in revenue, one can clearly see that the company is struggling to generate substantial income. This represents a significant decline compared to the same period a year ago.
To make matters worse, Singular Genomics Systems Inc also experienced a considerable net loss of $-25.578 million during the fiscal time-frame, which is even larger than the loss of $-23.982 million reported in the previous year. This alarming trend raises concerns about the company's ability to manage its expenses effectively and generate profitable operations.

Singular Genomics Systems Inc

Singular Genomics Systems Inc Shows Promising Growth Potential with Revenue of $0.863 Million in Latest Financial Report

Singular Genomics Systems Inc is setting the stage for incredible growth and profitability within the biotechnology and pharmaceuticals industry. While the company recorded a net deficit of $-23.633 million in the first quarter of 2023 earnings season, the substantial improvement in Return on Equity (ROE) compared to Q4 2022 is a clear indication of the company's progress towards reaching its financial goals.
As per the recent financial report released by the company, Singular Genomics Systems Inc disclosed revenue of $0.863 million, which is an impressive figure in itself. While some skeptics may point towards the net deficit of the company, it is essential to note that Singular Genomics Systems Inc is still a relatively young company immersed in a highly competitive industry.


Singular Genomics Systems Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com